Additionally, Usuda and colleagues reported that lung cancer patients with localized disease who expressed high levels of ABCG2 protein responded worse to porfimer sodium than patients with lower levels of ABCG2 [49], which further validated ABCG2 as a clinically-relevant mechanism of resistance in cancer. The gene discussed is ABCG2; the disease is lung cancer.